NCT05180968View on ClinicalTrials.gov

DIalysis Symptom COntrol-Pruritus Outcome Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
End Stage Renal DiseasePruritus
Interventions
DRUG

Nabilone 0.5 MG Oral Capsule

This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.

DRUG

Placebo Nabilone

This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.

Trial Locations (2)

T6G2P4

University of Alberta Hospital, Edmonton

R2V 3M3

Seven Oaks General Hospital, Winnipeg

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

lead

University of Manitoba

OTHER